Clinical Trial

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-31; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2025-09-19
Trial Details
NCT Number NCT07110571
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Gastric Cancer, Gastroesophageal-junction Cancer
Enrollment 200 participants
Start Date 2025-08-28
Primary Completion 2026-08 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-09